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I. Executive Summary
Maine currently requires that insurance carriers provide coverage for prosthetic devices
to replace all or part of an arm or leg. However, as currently written, the statute
specifically excludes prosthetic devices that contain microprocessor devices. LD 20, An
Act to Require Insurance Companies to Cover the Cost of Prosthetics, as amended would
require coverage for prosthetics employing microprocessors.
Currently most prosthetics employing microprocessor technology are used for knee
prosthetics. Microprocessor prosthetics for other applications are being developed and
are expected to be widely available for ankles, hands, elbows, etc. in the future.
Microprocessor knee prosthetics allow individuals to walk more naturally, with less
effort, and more stability than with prior technology. This results in fewer injuries due to
falls and improved benefit since the amputee does not tire as easily.
Coverage for microprocessor prosthetics is available through Workers Compensation
insurance, Medicare, MaineCare, the Veterans Administration (VA), and Tricare for
those who qualify.
To date, ten other states have adopted mandated prosthetic coverage, and none of these
states exclude coverage for microprocessor prosthetics from their mandate.
Cigna and UnitedHealthcare currently cover microprocessors. Due to the currently
limited utilization of microprocessors in prosthetic devices, Aetna believes that the cost
implications are immaterial, and Aetna expects no increases to premiums, administrative
expenses or indirect costs at this time. Mega Life estimates an impact of less than twotenths of one percent, but anticipates that this number will likely increase with new
technologies.
Anthem estimated the cost of this amendment based on the State of Maine Employee
Health Plan (SOM), which currently covers prosthetic devices with microprocessors.
For a 12-month experience period ending October 2009, the cost associated with the
SOM plan for prosthetics with microprocessors was approximately $0.11 per member
per month (PMPM). During that period, there were only two SOM members incurring
claims that listed “microprocessor” in the procedure description. Trending the $0.11
PMPM to be effective in a 2010 rating period, Anthem estimates the cost to be
approximately $0.12 PMPM for group products.
In their response to the Department’s survey, Harvard Pilgrim estimated the cost to be
under 0.1% of claims or approximately $0.30 PMPM. Moreover, based on Harvard
Pilgrim’s actual experience to date in Massachusetts and New Hampshire, use of these
devices is low, so the impact on a PMPM basis is much less (approximately $0.05
PMPM).
We estimate the initial premium increase for insured plans would be approximately
$0.15 PMPM or 0.05% of premium. Ultimately, this could increase to $0.35 or 0.11% of
premium.

1

For our cost estimates, we assumed that when the amendment is first implemented,
microprocessor prosthetics will be primarily for knees, but over time microprocessor
prosthetics will be available for ankles, wrists and elbows. We also assume that a
microprocessor prosthetic costs $32,000 more than a traditional prosthetic, that the
prosthetic will be eligible for replacement every 5 years (consistent with Medicare rules)
and that currently 28% of microprocessor prosthetics are covered by insurance.
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II. Background
The Joint Standing Committee on Insurance and Financial Services of the 124th Maine
Legislature directed the Bureau of Insurance (the Bureau) to review an amendment to LD
20, An Act to Require Insurance Companies to Cover the Cost of Prosthetics. The
review was conducted as required by 24-A M.R.S.A. § 2752. This review was a
collaborative effort of NovaRest, Inc. and the Bureau.
In 2004, Maine passed a mandated benefit requiring insurance carriers to cover
prosthetic devices to replace all or part of an arm or leg.1 The statute specifically
excludes prosthetic devices that contain microprocessors. As amended, LD 20 removes
this exemption from the existing mandated benefit.
Use of Prosthetics
Prosthetic devices are intended to restore function after limb loss. In 1999, the Food and
Drug Administration (FDA) first licensed prosthetics employing microprocessors for use
in the United States. Since then, technology advancements have greatly improved
mobility and functional capability. Numerous new models with improved function have
been introduced to the market. The use of prosthetics employing microprocessors for
above-the-knee amputees provides enhanced comfort, mobility and safety compared to
traditional prosthetic devices. These devices use microprocessor control for both the
swing and stance phases of gait. By improving stance control, they may provide
increased safety, stability, and function; for example, the sensors are designed to
recognize a stumble and stiffen the knee, thus avoiding a fall. Other potential benefits of
microprocessor controlled knee prostheses are improved ability to navigate stairs, slopes,
uneven terrain, and reduction of energy expenditure and concentration required for
ambulation.
The loss of a limb is most frequently due to:
• Diabetes related circulation problems (88%);
• Dysvascular disease (7.5%);
• Birth defect (under 4.2%);
• Bone cancer (0.1%); or
• Trauma (0.1%).2
The current rise in diabetes will probably result in a similar rise in related amputations
and the need for prosthetics. The Centers for Disease Control and Prevention reports
that: “[F]rom 1980 to 2005, the crude incidence of diagnosed diabetes increased 124%
from 3.3 per 1000 to 7.4 per 1000. Similarly, the age-adjusted incidence increased
114%, suggesting that the majority of the change was not due to the aging of the
population.”3

1

24-A M.R.S.A. § 4315
Health Care Utilization Project National Inpatient Sample (HCUP-NIS), 1996
3
http://www.cdc.gov/diabetes/statistics/incidence/fig2.htm
2

3

The rate of amputation in the US is approximately 4.9 per 1,000 people and 49% of
individuals with limb loss are under 65 years of age.4
Prosthetics employing microprocessors have been covered by Medicare since 2002. In
addition to Maine, ten other states mandate insurance coverage for prosthetics. Maine is
the only one of the 11 states that excludes prosthetics employing microprocessors.

4

http://www.amputee-coalition.org/fact_sheets/limbloss_us.html
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III. Social Impact
A.

Social Impact of Mandating the Benefit

1. The extent to which the treatment or service is utilized by a significant portion of the
population.
This benefit would be used by a very small portion of the population. Currently,
microprocessor prosthetics are most commonly used in above-knee amputation. They
are generally used within the knee joint to allow for stable walking. However, there is
growing research and development of microprocessor prosthetics for upper limb
amputations, including elbow and hand. It is not expected that these uses will have a
significant effect on the cost estimates at this time, but as new products are developed
and introduced into the market place, they could have a more significant effect in the
future.
In 2007, there were an estimated 105,392 hospital discharges nationally where lower
extremities were amputated.5 This results in an estimated rate of 3.5 lower extremity
amputations per 10,000 people.6 Using the same database, the estimated number of
hospital discharges where lower extremities were amputated in Maine was 432 per year.
Based on the national and Maine hospital discharge data, the age distribution for lower
extremity amputation is as follows:

Age
1-17
18-44
45-64
65-84
85+

Total number of
discharges of Amputation
Patients, Nationally
375 (0.36%)
9,435 (8.95%)
41,934 (39.78%)
43,747 (41.51%)
9,861 (9.36%)

Maine Amputation
discharges
*7
39 (9.03%)
158 (36.57%)
183 (42.36%)
52 (12.04%)

Additional data contained in the national and Maine hospital discharge data shows the
following information regarding payer of the service:

5

Agency for Healthcare Research and Quality, www.ahrq.gov
Calculations based on estimated 2007 populations estimates of the U.S. Census Bureau, www.census.gov
7
We interpret the asterisks to mean that although discharges were negligible in these categories, they are
possible.
6
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Payer
Medicare
Medicaid
Private Insurance
Uninsured
Other
Missing

Total number of
discharges of Amputation
Patients, Nationally
65,784 (62.42%)
11,251 (10.68%)
19,753 (18.74%)
5,203 (4.94)
3,222 (3.08%)
178 (0.17%)

Maine Amputation
discharges
310 (71.76%)
37 (8.56%)
68 (15.74%)
*
*
*

Based on the above data, the total number of new amputations of lower extremities
within the state of Maine that would be covered by private insurance would be in the
range of 60 to 70 per year. This includes those covered by self-insured plans, which are
not subject to Maine’s mandate.
Since the above numbers cover all amputations of lower extremities, statistical data is
not available to accurately estimate the number of Maine patients who would be
candidates for microprocessor prosthetics. Data indicates that between 19% and 40% of
lower amputations are for above-knee amputations.
Currently, microprocessor
prosthetics are most suitable for above-knee amputations.
Not everyone with the loss of a limb, even in the case of above-knee amputation, is a
good candidate for a microprocessor prosthetic or for any prosthetic device. The
decision on the appropriateness of a prosthetic device is based on the individual’s
functional abilities and other factors, including:
•
•
•
•
•

Physical condition of the residual limb;
Compounding health issues such as vascular or arthritic problems in the nonamputated appendages which may affect prosthetic wear;
Demographic and lifestyle factors including employment and activity levels;
Independent living status; and
Timeframes for recovery and access to rehabilitative care.8

Based on the above, it can be estimated that this benefit would affect less than 35 new
above-knee amputees per year in the State of Maine plus replacement prosthetics for
current Maine amputees. Using our assumptions (see financial impact below),
approximately 20 amputees initially and 50 amputees ultimately would benefit from this
mandate every year.
2. The extent to which the service or treatment is available to the population.
Prosthetics employing microprocessors are readily available in the State of Maine.
There are at least four major manufacturers of microprocessor knees available.
3. The extent to which insurance coverage for this treatment is already available.

8

Joint Legislative Audit and Review Commission of the Virginia General Assembly; Evaluation of Senate
Bill 931; September 2007
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If a loss of limb is due to a work-related injury, it may be covered by Worker’s
Compensation. In general, the employer/insurer is liable for all reasonable medical and
hospital services, appliances, prescribed drugs, prosthetic devices, and other supplies that
are necessary as the result of a work-related injury.
The Veterans Administration (VA) covers the expense for the loss of limb of veterans
with qualifying service. Tricare covers active military members and their families, as
well as military retirees under age 65 and their families.
If the patient qualifies for Medicare due to age or disability, Medicare covers 80% of the
scheduled reimbursement amounts for prosthetics after an annual Part B deductible is
satisfied. Enrollment in Medicare Advantage plans or Medicare supplement insurance
may result in additional coverage.
MaineCare reported that as of January 1, 2010, they are now covering microprocessors in
knees that they previously would have denied. They currently do not cover
microprocessors for other prosthetics due to the cost involved.
In Maine, carriers are required to cover non-microprocessor prosthetics to the same
extent as Medicare to replace all or part of an arm or leg. Even though prosthetics are
covered by insurance, some insurers do not cover microprocessor prosthetics,
considering them as experimental devices and exclude them on that basis.9
Carriers reported the following information:
Aetna
Aetna currently provides microprocessor prosthetic coverage for lower extremities if
approved for medical necessity based on its clinical policy guidelines. Aetna considers
ankle-foot prostheses with microprocessor experimental, so are they are currently
not covered.
Anthem
Anthem does not provide benefits for prosthetic devices to replace, in whole or in part,
an arm or a leg that are designed exclusively for athletic purposes or that contain a
microprocessor. They do cover prosthetics with a microprocessor under the State of
Maine employee plan.
Cigna
Cigna currently covers all prosthetics as currently mandated and also provides for the
coverage of prosthetics with microprocessors, after medical necessity review, if the
benefit is not a specific benefit exclusion. For 2009 Cigna approved three such devices,
and the cost to members was zero.
Harvard Pilgrim
Harvard Pilgrim only covers prosthetics to the extent of the current mandate and,
therefore, does not cover microprocessor prosthetics.
Mega Life
9

Amputee Coalition of America, Microprocessor Devices: The Facts
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For Mega Life policies, microprocessor controlled prosthetics are excluded, either in an
amendatory endorsement or in the definition.
United Healthcare
United Healthcare currently covers microprocessor prosthetics.

4. If coverage is not generally available, the extent to which the lack of coverage
results in a person being unable to obtain the necessary health care treatment.
Due to the high cost of microprocessor prosthetics, many patients may not be able to
afford these devices without the help of insurance.
The average cost of an above-knee prosthetic is approximately $20,000 - $30,000. One
Maine provider indicates that the current cost of a knee prosthetic with a microprocessor
is approximately $57,000.
5. If coverage is not generally available, the extent to which the lack of coverage
involves unreasonable financial hardship.
As noted above, the costs of these devices can be very significant. As stated by the
Amputee Coalition of America:10
When individuals discover that prosthetic care is not covered by their
health insurer, or it is extremely limited, they resort to use of
retirement funds or children’s college savings to purchase the
prosthesis they need…. Some individuals in this situation have even
taken mortgages out on their homes to get the prosthesis they need.
6. The level of public demand and the level of demand from providers for this
treatment or service.
It is estimated that this service is required approximately 78 times per year for new and
replacement prosthetics in Maine for those under age 65 and that approximately 20 of
these are covered by insurance that does not cover microprocessor prosthetics.
7. The level of public demand and the level of demand from the providers for
individual or group coverage of this treatment.
A number of amputee advocacy groups strongly encourage LD 20. Groups include:
• Amputee Coalition of America
• Maine Coalition of Working Amputees
• Disability Rights Center
In addition, at least ten Maine residents have written to express their support for this bill.
10

Amputee Coalition of America, Advocacy News: Federal Prosthetic Coverage Bill Released, March 17,
2008
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8. The level of interest in and the extent to which collective bargaining organizations
are negotiating privately for the inclusion of this coverage by group plans.
No information is available.
9. The likelihood of meeting a consumer need as evidenced by the experience in other
states.
There are no studies indicating the actual consumer experience in other states. Ten other
states have mandated prosthetic benefits. None of these states exclude microprocessor
prosthetics from the mandate. Virginia’s mandate was effective January 1, 2010, and the
Virginia Bureau of Insurance does not expect to have experience data to report until May
2011, as part of their annual report on the impact of mandated benefits.
10. The relevant findings of the state health planning agency or the appropriate
health system agency relating to the social impact of the mandated benefit.
No information was provided by the state health planning agency.
11. The alternatives to meeting the identified need.
No alternatives to meeting the identified need were presented.
12. Whether the benefit is a medical or a broader social need and whether it is
inconsistent with the role of insurance and the concept of managed care.
The benefit is a medical need due to a physical condition, and coverage required by LD
20 is not inconsistent with the role of insurance to provide medically necessary devices
for a condition.
13. The impact of any social stigma attached to the benefit upon the market.
The loss of a limb and the disability resulting from it often causes amputees to feel social
stigma because they are not able to do what a “normal” person can do. The use of
prosthetics, especially microprocessor prosthetics, allows an amputee to resume more of
the usual activities of daily living.
14. The impact of this benefit upon the other benefits currently offered.
Studies have shown that the use of microprocessor prosthetics has reduced other future
health claims of users.11 Because of the performance of these prosthetics, users report
fewer falls while wearing microprocessor controlled prosthetic devices; therefore, the
incidence of other injuries, such as broken hips requiring surgery is reduced.

11

Hafner, BJ, Willingham, LL, Buell NC, Allyn KJ, Smith DG, Evaluation of Function, Performance, and
Preference as Transfemoral Amputee, Transition from Mechanical to Microprocessor Control of the
Prosthetic Knee , Archives of Physical Medicine and Rehabilitation, Volume 88, Issue 2, Pages 207-217
(February 2007)
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In addition, the use of these devices results in users being more active since they allow
for more mobility with less effort.
15. The impact of the benefit as it relates to employers shifting to self-insurance and
the extent to which the benefit is currently being offered by employers with selfinsured plans.
As premiums increase due to mandated benefits, some employers may choose to selfinsure in order to have more control over the benefits that they provide to employees and
the cost of health insurance premiums.
16. The impact of making the benefit applicable to the state employee health insurance
program.
The State Employee Health Plan currently provides coverage for prosthetic devices with
microprocessors; therefore, there would not be any cost implications for the plan.
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IV. Financial Impact
B. Financial Impact of Mandating Benefits.
1. The extent to which the proposed insurance coverage would increase or decrease
the cost of the service or treatment over the next five years.
Due to the level of current competition, it is expected that implementation of this
coverage would not have any effect on the cost of microprocessor prosthetics over the
next five years.
2. The extent to which the proposed coverage might increase the appropriate or
inappropriate use of the treatment or service over the next five years.
The coverage of microprocessor prosthetics by insurance would increase the use of these
devices. It could increase inappropriate use if prescribed for patients who normally
would not be candidates for these devices. Health insurers could use managed care
practices to control the misuse of the benefit.
The Amputee Coalition of America, states:
The provision of prostheses is done on a case by case basis using a
proven set of criteria that takes into account the individual’s potential
for rehabilitation or achievement of a function level, as well as their
age, vocation and any other health conditions.12
Hanger Prosthetics & Orthotics, a major provider of prosthetics in the United States with
more than 600 locations nationwide provided a copy of a detailed Patient Assessment
Validation Evaluation Test used to determine the suitability of an individual for
prosthetics.
3. The extent to which the mandated treatment or service might serve as an alternative
for more expensive or less expensive treatment or service.
The mandated coverage of microprocessor prosthetics would, in some cases, replace
other less expensive traditional prosthetics.
4. The methods which will be instituted to manage the utilization and costs of the
proposed mandate.
This amendment does not prohibit health plans from covering the services with the same
medical management used for other services.
5. The extent to which insurance coverage may affect the number and types of
providers over the next five years.

12

Amputee Coalition of America, LD20: Making the Case for Comprehensive Prosthetic Provision
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It is not anticipated that this mandate would have any effect on the number and types of
providers over the next five years.
6. The extent to which the insurance coverage of the health care service or providers
may be reasonably expected to increase or decrease the insurance premium or
administrative expenses of policyholders.
The increase in premiums may vary over time, if this amendment is enacted. If this
amendment becomes effective, there may be a backlog of individuals who currently
cannot afford a microprocessor prosthetic and would want to replace their current
prosthetic with a new microprocessor device. LD 20 as amended only requires
replacement every five years, consistent with Medicare, but there may still be an increase
in demand.
Over time, we anticipate microprocessor prosthetics for other uses. Microprocessor
prosthetic ankles and hands are already being perfected, and prosthetic elbows may be
available in the future. This will increase the cost of this mandate going forward, but we
cannot estimate the extent with any precision. The cost of these newly developed
prosthetics may also decrease over time if there is increased competition in the
manufacturing of these devices.
We estimate a premium increase initially of $0.15 per member per month (PMPM), with
a potential increase of $0.35 PMPM as other types of prosthetics are developed with
microprocessors.
Our estimate is based on the following assumptions:
1)
2)
3)
4)
5)
6)
7)

8)

There are 4.9 amputees per 1,00013, 49% of whom are under age 65.
There are 13 new above-knee amputees in Maine every year.
34% of amputations are above-knee amputations.14
46% of above-knee amputees use prosthetics, and 60% of all amputees use
prosthetics.15
75% of above-knee prosthetics users would use microprocessor prosthetics, and
eventually 50% of all prosthetic users would use microprocessor prosthetics.
The prosthetics used every year include the new prosthetics and 20% of the existing
prosthetics as replacements (Medicare approves replacements every 5 years).
32%16 of under age 65 amputees are covered by private insurance, excluding selfinsurance, and 28%17 of insurance policies currently cover microprocessor
prosthetics.
The cost of a microprocessor prosthetic is approximately $32,000 more than a nonmicroprocessor prosthetic.

13

Centers for Disease Control and Prevention, "Improving the Lives of People with Limb Loss",
http://www.cdc.gov/programs/bd04.htm
14
Joint Legislative Audit and Review Commission of the Virginia General Assembly; Evaluation of Senate
Bill 931; September 2007
15
Joint Legislative Audit and Review Commission of the Virginia General Assembly; Evaluation of Senate
Bill 931; September 2007
16
Agency for Healthcare Research and Quality, www.ahrq.gov
17
Based on carrier responses and carrier membership information
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Insurers’ estimates of premium increases are as follows:
Aetna
Aetna has a small block of individual plans in Maine and has not issued a rate increase in
that block for several years. For group plans, Aetna believes that the cost implications
are immaterial due to the limited number of their insureds using microprocessors in
prosthetic devices. Therefore, Aetna expects no increases to premiums, administrative
expenses or indirect costs at this time.
Anthem
Anthem estimated the cost of this amendment based on the State of Maine Employee
Health Plan (SOM), which currently covers prosthetic devices with microprocessors.
For a 12-month experience period ending October 2009, the cost associated with the
SOM plan for prosthetics with microprocessors was approximately $0.11 PMPM.18
During that period, there were only two SOM members incurring claims that listed
“microprocessor” in the procedure description. Trending the $0.11 PMPM to be
effective in 2010 rating period, Anthem estimates the cost to be approximately $0.12
PMPM for group products.
Cigna
Cigna reports that the financial and utilization implications that would drive pricing for
all policies appears to be minimal as Cigna currently covers microprocessors, after
medical necessity review is performed, in plans that do not exclude the benefit. The
overall volume requested for this benefit is low.
Harvard Pilgrim
In their response to the Department’s survey, Harvard Pilgrim said that an equivalent
myoelectric or bionic device19 could cost up to three times a standard prosthetic device.
However, they indicate that few members require a myoelectric or bionic prosthetic, so
their actuaries have estimated the cost to be under 0.1% of claims or approximately
$0.30 PMPM. Moreover, based on Harvard Pilgrim’s actual experience to date in
Massachusetts and New Hampshire, use of these devices is low, so the impact on a
PMPM basis is much less (approximately $0.05 PMPM). In both Massachusetts and
New Hampshire, the myoelectric or bionic devices are subject to the same standard for
coverage as regular prostheses, i.e., the most appropriate model that adequately meets the
member's needs in the performance of activities of daily living.
Mega Life
Mega Life estimates an impact of less than two-tenths of one percent, but anticipates that
this number will likely increase with new technologies.
United Healthcare
United Healthcare currently covers microprocessor prosthetics and therefore there would
be no increase in premium.

18

Per member per month
A myoelectric device uses electromyogram signals or potentials from voluntarily contracted muscles. A
bionic device uses microcircuits. Both are types of microprocessor prosthetics.
19
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7. The impact of indirect costs, which are costs other than premiums and
administrative costs, on the question of the cost and benefits of coverage.
There would not be any additional cost effect beyond benefit and administrative costs.
8. The impact on the total cost of health care, including potential benefits and savings
to insurers and employers because the proposed mandated treatment or service
prevents disease or illness or leads to the early detection and treatment of disease or
illness that is less costly than treatment or service for later stages of a disease or
illness.
The total cost of health care would increase to the extent that non-microprocessor
prosthetics are replaced with the more expensive microprocessor units. This cost will
increase as microprocessor technology is applied to additional types of prosthetics. As
previously noted, the price of some microprocessor prosthetics, however, may decrease
over time with greater competition in manufacturing.
Microprocessor knee prosthetics reduce the chance of falling. This will result in fewer
injuries from falls, including broken hips and other bones. No data is available to
quantify the cost of the reduction in injuries due to falls.
9. The effects of mandating the benefit on the cost of health care, particularly the
premium and administrative expenses and indirect costs, to employers and employees,
including the financial impact on small employers, medium-sized employers and large
employers.
Some insurers currently cover microprocessor prosthetics, and their premiums would be
unaffected. Estimates from carriers that do not currently cover microprocessor
prosthetics range from minimal to $0.30 PMPM
We estimate that the average premium would increase approximately $0.15 PMPM the
first year that the amendment is implemented and as much as $0.35 PMPM as
microprocessor prosthetics for other applications become available.
10. The effect of the proposed mandates on cost-shifting between private and public
payers of health care coverage and on the overall cost of the health care delivery
system in this State.
To the extent that these services are currently covered by MaineCare and will be paid for
by private insurance after the mandate is implemented, the cost will be shifted from the
public payers to the private payers. MaineCare is not currently covering a significant
number of microprocessor prosthetics that would be paid for by insurers due to this
amendment.
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V. Medical Efficacy
C.

The Medical Efficacy of Mandating the Benefit.
1. The contribution of the benefit to the quality of patient care and the health status of
the population, including any research demonstrating the medical efficacy of the
treatment or service compared to the alternative of not providing the treatment or
service.
A study published in the Archives of Physical Medicine and Rehabilitation compared the
effect of active microprocessor control and passive mechanical control of the prosthetic
knee on function and safety in 21 unilateral, transfemoral amputees. It concluded:
This study examined the functional ability, performance, and satisfaction of
transfemoral amputee subjects during the transition from an established,
mechanical control prosthetic knee system into a microprocessor control
Otto Bock C-Leg. This transition mirrors the common clinical practice of
prescribing a microprocessor control knee after demonstration of proficient
and successful use of a mechanical control knee unit. Although anecdotal
evidence suggests that microprocessor control of the prosthetic knee may
offer increased performance in functional tasks such as stair descent, ramp
and hill descent, walking on uneven terrain, a reduction in cognitive demand
while walking, and increased safety, empirical evidence for such benefits has
been limited. The results shown in this investigation show a statistically
significant improvement in subjects’ ability to descend stairs; time required
to descend a slope; sound-side step length while descending a hill;
preference; satisfaction; self-reported frustration with falling; and selfreported frequency of stumbles, semi controlled falls, and uncontrolled falls
while wearing the microprocessor control knee and population trends of 5%
or more improvement in a number of other functional categories. The results
of this investigation not only highlight measured differences between the
microprocessor and mechanical control of a knee component but also offer
several new techniques and associated outcome measures for assessing
function in the transfemoral amputee population. Because it is in functional
areas beyond level walking that the benefits of microprocessor control are
most observed, the development and standardized use of tools to assess
function in these domains is critical to our understanding of real-world
amputee ability, performance, and preference. This research has shown that
microprocessor control provides significant benefit over mechanical control
of the prosthetic knee. It is hoped that this information encourages and
promotes additional research in these and other potential benefits of
20
microprocessor stance-phase control in lower-limb prosthetics.

20

Hafner BJ, Willingham LL, Buell NC, Allyn KJ, Smith DG., Evaluation of Function, Performance, and
Preference as Transfemoral Amputees Transition From Mechanical to Microprocessor Control of the
Prosthetic Knee. Volume 88, Issue 2, Pages 207-217 (February 2007)
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An additional study by Seymour et al showed positive results for improved function with
the use of microprocessor-controlled prosthesis. 21 The study conducted observations of
participant’s ability to traverse an obstacle course meant to replicate walking tasks that
they would encounter in real-life. Participants were able to complete the obstacle course
faster, with fewer steps, while wearing the C-leg. These results were retained when the
participants carried a ten pound laundry basket while walking the course.
2. If the legislation seeks to mandate coverage of an additional class of practitioners:
This amendment does not mandate coverage of an additional class of practitioners.
a. The results of any professionally acceptable research demonstrating medical results
achieved by the additional practitioners relative to those already covered.
Not applicable.
b. The methods of the appropriate professional organization that assure clinical
proficiency.
Not applicable.

21

Seymour R, Engbrestson B, Kott K, Comparison between the C-leg microprocessor-controlled prosthetic
knee and non-microprocessor-controlled prosthetic knees; a preliminary study of energy expenditure,
obstacle course performance, and quality of life survey, Prosthet Orthot Int. 2007, 31(1):5161

16

VI. Balancing the Effects
D. The Effects of Balancing the Social, Economic, and
Medical Efficacy Considerations.
1. The extent to which the need for coverage outweighs the cost of mandating the
benefit for all policyholders.
It is estimated that 78 under age 65 amputees in Maine will require new or replacement
above-knee prosthetics and would use a microprocessor prosthetic. Of these, 32% are
covered by insurance, excluding self-insurance, but 28% of the insured already have
microprocessor coverage, resulting in approximately 20 above-knee amputees potentially
benefiting per year. As microprocessor prosthetics are available for other purposes,
approximately 50 individuals per year will benefit.
The use of a microprocessor prosthetic enhances the usefulness of the prosthetic. For
knees, the prosthetic allows for smoother walking and uses less effort allowing for
walking longer distances. The use of a microprocessor knee prosthetic also results in
fewer falls and injuries from falls, although the savings have not been quantified.
Similar improved usefulness can be expected for other microprocessor prosthetics as
they are developed.
2. The extent to which the problem of coverage can be resolved by mandating the
availability of coverage as an option for policyholders.
Since this mandate would impact a very small percentage of the total population, it is
likely that only those who would benefit from the services would purchase the coverage.
This would result in an alternative coverage that would cost more than the cost of
services when administrative charges were added to benefit costs. This cost would be
reduced if the option was only available when the coverage was initially purchased, but
then it would be less effective since many individuals may not believe that they will need
the coverage and, therefore, would not purchase it.

3. The cumulative impact of mandating this benefit in combination with existing
mandates on costs and availability of coverage.
The Bureau’s estimates of the premium increases due to existing mandates are displayed
in Appendix B. We anticipate that this bill would initially increase premiums by
approximately $0.15 PMPM and ultimately increase insured premiums22 by
approximately $0.35 PMPM. This represents 0.05% percent of premium initially and
0.11% ultimately.

22

This mandate would not apply to self-insured groups.
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The following table contains the current estimate of the total cost of mandates in the state of
Maine.
Cost of Mandated Benefits in Maine

Est. Maximum Cost as % of Premium
Prior to
Amendment
NonHMO

HMO

Initial After
Amendment
NonHMO

HMO

Ultimate After
Amendment
NonHMO

HMO

Total cost for groups larger than 20:

6.85%

7.32%

6.90%

7.37%

6.96%

7.43%

Total cost for groups of 20 or fewer:

3.75%

5.52%

3.80%

5.57%

3.86%

5.63%

Total cost for individual contracts:

3.74%

4.12%

3.79%

4.17%

3.85%

4.23%
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Appendix A: Letter from the Committee on Insurance and
Financial Services with Proposed Legislation
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Appendix B: Cumulative Impact of Mandates in Maine
Following are the estimated claim costs for the existing mandates:


Mental Health (Enacted 1983) – The mandate applies only to group plans. It applies to all group HMO plans
but does not apply to non-HMO employee group plans covering 20 or fewer employees. Mental health parity
for listed conditions was effective 7/1/96 but does not apply to any employer with 20 or fewer employees,
whether under HMO or other coverage. The list of conditions for which parity is required was expanded
effective 10/1/03. Using annual experience reports from the carriers, the percentage of mental health claims
paid has been tracked since 1984 and has historically been between 3% and 4% of total group health claims.
The percentage was in the 3.27% to 3.47% range from 1998 to 2002 but then decreased, reaching 2.62% in
2007 and 2.60% in 2008. The percentage of claims is further broken out by HMO and other health plans, but
the relationship is inconsistent from year to year. The continued decrease in mental health claims occurred
despite the fact that an expansion of the list of conditions for which parity is required was fully implemented
in 2005. We estimate a continuation of 2008 levels going forward. For HMO plans covering employers with
20 or fewer employees, we use half the value for larger groups to reflect the fact that parity does not apply.
Although it is likely that some of these costs would be covered even in the absence of a mandate, we have no
basis for estimating how much. We have included the entire amount, thereby overstating the impact of the
mandate to some extent. However, this overstatement is at least partially offset by the fact that the data is an
aggregate of all groups, while groups of 20 or fewer are exempt from the parity requirement in the case of
HMO coverage and from the entire mandate in the case of non-HMO coverage.



Substance Abuse (Enacted 1983) – The mandate applies only to groups of more than 20 and originally did
not apply to HMOs. Effective 10/1/03, substance abuse was added to the list of mental health conditions for
which parity is required. This applies to HMOs as well as other carriers. Using annual experience reports
from the carriers, the percentage of claims paid has been tracked since 1984. Until 1991, it was in the range
of 1% to 2% of total group health claims. This percentage showed a downward trend from 1989 to 2000
when it reached 0.31%. It then increased and leveled off at a range of 0.55% to 0.72% for 2002 through
2008 (low of 0.55% in 2008, high of 0.72% in 2006) despite implementation of the parity requirement. The
long-term decrease was probably due to utilization review, which sharply reduced the incidence of inpatient
care. Inpatient claims decreased from about 93% of the total in 1985 to 34% in 2008. The percentage of
claims is further broken out by HMO and other health plans, but the relationship is inconsistent from year to
year. We estimate substance abuse benefits will remain at the current levels going forward. Although it is
likely that some of these costs would be covered even in the absence of a mandate, we have no basis for
estimating how much. We have included the entire amount, thereby overstating the impact of the mandate to
some extent. However, this overstatement is offset by the fact that the data is an aggregate of all groups,
while the mandate applies only to groups larger than 20.



Chiropractic (Enacted 1986) – Using annual experience reports from the carriers, the percentage of claims
paid has been tracked since 1986 and has been approximately 1% of total health claims each year. However,
the percentage increased from 0.84% in 1994 to a high of 1.51% in 2000. Since then, it has decreased to
1.13% in 2008. In the past, the level was lower for individual than for group, but individual has increased to
about the same level as group. The level does vary between HMOs and other plans. For 2008, the
percentages were 1.30% for HMO plans and 0.95% for other plans. We estimate the current levels going
forward. Although it is likely that some of these costs would be covered even in the absence of a mandate,
we have no basis for estimating how much. We have included the entire amount, thereby overstating the
impact of the mandate to some extent.
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Screening Mammography (Enacted 1990) – Using annual experience reports from the carriers, the
percentage of claims paid has been tracked since 1992. It increased from 0.11% of total claims in 1992 to
0.7% in 2002 and has remained at about this level since then. There was no significant difference between
HMO plans and other plans for group coverage. Recently, the U.S. Preventive Services Task Force
recommended that screening mammograms begin at a later age and be done less frequently. While it is
possible this will lead to reduced utilization, the American Cancer Society, the American College of
Obstetricians and Gynecologists, and many oncologists have not accepted these recommendations. We
therefore estimate the past level of 0.7% in all categories going forward.



Dentists (Enacted 1975) – This mandate requires coverage to the extent that the same services would be
covered if performed by a physician. It does not apply to HMOs. A 1992 study done by Milliman and
Robertson for the Mandated Benefits Advisory Commission estimated that these claims represent 0.5% of
total health claims and that the actual impact on premiums is "slight." It is unlikely that this coverage would
be excluded in the absence of a mandate. We include 0.1% as an estimate.



Breast Reconstruction (Enacted 1998) – At the time this mandate was being considered in 1995, Blue Cross
and Blue Shield of Maine estimated the cost at $0.20 per month per individual. We do not have a more
recent estimate. We include 0.02% in our estimate of the maximum cumulative impact of mandates.



Errors of Metabolism (Enacted 1995) – At the time this mandate was being considered in 1995, Blue Cross
estimated the cost at $0.10 per month per individual. We do not have a more recent estimate. We include
0.01% in our estimate.



Diabetic Supplies (Enacted 1996) – Our report on this mandate indicated that most of the 15 carriers
surveyed in 1996 said there would be no cost or an insignificant cost because they already provide coverage.
One carrier said it would cost $.08 per month for an individual. Another said .5% of premium ($.50 per
member per month) and a third said 2%.
We include 0.2% in our estimate.



Minimum Maternity Stay (Enacted 1996) – Our report stated that Blue Cross did not believe there would be
any cost for them. No other carriers stated that they required shorter stays than required by the bill. We
therefore estimate no impact.



Pap Smear Tests (Enacted 1996) – No cost estimate is available. HMOs would typically cover these
anyway. For non-HMO plans, the relatively small cost of this test would not in itself satisfy the deductible,
so there would be no cost unless other services were also received. We estimate a negligible impact of
0.01%.



Annual GYN Exam Without Referral (managed care plans) (Enacted 1996) – This only affects HMO plans
and similar plans. No cost estimate is available. To the extent the Primary Care Physician (PCP) would, in
absence of this law, have performed the exam personally rather than referring to an OB/GYN, the cost may
be somewhat higher. We include 0.1%.



Breast Cancer Length of Stay (Enacted 1997) – Our report estimated a cost of 0.07% of premium.



Off-label Use Prescription Drugs (Enacted 1998) – The HMOs claimed to already cover off-label drugs, in
which case there would be no additional cost. However, providers testified that claims have been denied on
this basis. Our 1998 report did not resolve this conflict but stated a "high-end cost estimate" of about $1 per
member per month (0.6% of premium) if it is assumed there is currently no coverage for off-label drugs. We
include half this amount, or 0.3%.
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Prostate Cancer (Enacted 1998) – No increase in premiums should be expected for the HMOs that provide
the screening benefits currently as part of their routine physical exam benefits. Our report estimated
additional claims cost for non-HMO plans would approximate $0.10 per member per month. With the
inclusion of administrative expenses, we would expect a total cost of approximately $0.11 per member per
month, or about 0.07% of total premiums.



Nurse Practitioners and Certified Nurse Midwives (Enacted 1999) – This law mandates coverage for nurse
practitioners and certified nurse midwives and allows nurse practitioners to serve as primary care providers.
This mandate is estimated to increase premium by 0.16%.



Coverage of Contraceptives (Enacted 1999) – Health plans that cover prescription drugs are required to
cover contraceptives. This mandate is estimated to increase premium by 0.8%.



Registered Nurse First Assistants (Enacted 1999) – Health plans that cover surgical first assisting are
mandated to cover registered nurse first assistants if an assisting physician would be covered. No material
increase in premium is expected.



Access to Clinical Trials (Enacted 2000) – Our report estimated a cost of 0.19% of premium.



Access to Prescription Drugs (Enacted 2000) – This mandate only affects plans with closed formularies.
Our report concluded that enrollment in such plans is minimal in Maine and therefore the mandate will have
no material impact on premiums.



Hospice Care (Enacted 2001) – No cost estimate was made for this mandate because the Legislature waived
the requirement for a study. Since carriers generally cover hospice care already, we assume no additional
cost.



Access to Eye Care (Enacted 2001) – This mandate affects plans that use participating eye care
professionals. Our report estimated a cost of 0.04% of premium.



Dental Anesthesia (Enacted 2001) – This mandate requires coverage for general anesthesia and associated
facility charges for dental procedures in a hospital for certain enrollees for whom general anesthesia is
medically necessary. Our report estimated a cost of 0.05% of premium.



Prosthetics (Enacted 2003) – This mandate requires coverage for prosthetic devices to replace an arm or leg.
Our report estimated a cost of 0.03% of premium for groups over 20 and 0.08% for small employer groups
and individuals.



LCPCs (Enacted 2003) – This mandate requires coverage of licensed clinical professional counselors. Our
report on mental health parity indicated no measurable cost impact for coverage of LCPCs.



Licensed Pastoral Counselors and Marriage & Family Therapists (Enacted 2005) – This mandate requires
coverage of licensed pastoral counselors and marriage & family therapists. Our report indicated no
measurable cost impact for this coverage.



Hearing Aids (Enacted 2007) – This mandate requires coverage for $1,400 for each ear every 36 months for
children age 18 and under. The mandate is phased-in by requiring coverage from birth to age 5 effective
1/08, age 6-13 effective 1/09 and age 14-18 effective 1/10. Our report estimated a cost of 0.1% of premium
once fully implemented.
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Infant Formulas (Enacted 2008) – This mandate requires coverage for amino acid-based elemental infant
formulas for children 2 years of age and under, regardless of delivery method. Our report estimated a cost of
0.1% of premium.



Colorectal Cancer Screening (Enacted 2008) – This mandate requires coverage for colorectal cancer
screening for persons fifty years of age or older, or less than 50 years of age and at high risk for colorectal
cancer according to the most recently published colorectal cancer screening guidelines of a national cancer
society. No carriers stated they denied coverage, therefore our report estimated no impact on premium.



Independent Dental Hygienist (Enacted 2009) – This mandate requires individual dental insurance or

health insurance that includes coverage for dental services to provide coverage for dental services
performed by an independent practice dental hygienist. This mandate is effective 1/2010. This mandate
applies only to policies with dental coverage; therefore, there is no estimated impact on medical plan
premiums.
These costs are summarized in the following table:

COST OF EXISTING MANDATED HEALTH INSURANCE BENEFITS
Year
Enacted

Benefit

1975

Maternity benefits provided to married women must also be
provided to unmarried women.

All Contracts

1975

Must include benefits for dentists’ services to the extent that the
same services would be covered if performed by a physician.

All Contracts except
HMOs

1975
1983

Type of Contract
Affected

Family Coverage must cover any children born while coverage is
in force from the moment of birth, including treatment of
congenital defects.
Benefits must be included for treatment of alcoholism and drug
dependency.

Groups of more than
20
Groups of more than
20

Benefits must be included for Mental Health Services, including
psychologists and social workers.

1986
1994
1995
1997

Benefits must be included for the services of chiropractors to the
extent that the same services would be covered by a physician.
Benefits must be included for therapeutic, adjustive and
manipulative services. HMOs must allow limited self referred for
chiropractic benefits.

1990
1997

Benefits must be made available for screening mammography.

1995

Must provide coverage for reconstruction of both breasts to
produce symmetrical appearance according to patient and
physician wishes.

All Contracts

Must provide coverage for metabolic formula and up to $3,000
per year for prescribed modified low-protein food products.

All Contracts
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Non-HMO

Groups of 20 or
fewer

HMO

01

01

0.10%

--

01

--

0.55%

0.55%

2.60%

2.60%

All Contracts except
HMOs

1975
1983
1995
2003

1995

Est. Maximum Cost
as % of Premium

--

1.30%

Group

0.95%

1.30%

Individual

0.95%

1.30%

Group

0.70%

0.70%

Individual

0.70%

0.70%

0.02%

0.02%

0.01%

0.01%

Year
Enacted

Benefit

Type of Contract
Affected

1996

Benefits must be provided for maternity (length of stay) and
newborn care, in accordance with “Guidelines for Prenatal Care.”

1999
1999
2000

Benefits must be provided for medically necessary equipment and
supplies used to treat diabetes and approved self-management and
education training.
Benefits must be provided for screening Pap tests.
Benefits must be provided for annual gynecological exam
without prior approval of primary care physician.
Benefits provided for breast cancer treatment for a medically
appropriate period of time determined by the physician in
consultation with the patient.
Coverage required for off-label use of prescription drugs for
treatment of cancer, HIV, or AIDS.
Coverage required for prostrate cancer screening.
Coverage of nurse practitioners and nurse midwives and allows
nurse practitioners to serves as primary care providers.
Prescription drug must include contraceptives.
Coverage for registered nurse first assistants.
Access to clinical trials.

2000

Access to prescription drugs.

2001

Coverage of hospice care services for terminally ill.

2001

Access to eye care.

2001

Coverage of anesthesia and facility charges for certain dental
procedures.

2003

Coverage for prosthetic devices to replace an arm or leg

2003

Coverage of licensed clinical professional counselors
Coverage of licensed pastoral counselors and marriage & family
therapists
Coverage of hearing aids for children
Coverage for amino acid-based elemental infant formulas
Coverage for colorectal cancer screening
Coverage for independent dental hygienist
Total cost for groups larger than 20:
Total cost for groups of 20 or fewer:
Total cost for individual contracts:

1996
1996
1996
1997
1998
1998
1999

2005
2007
2008
2008
2009
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Est. Maximum Cost
as % of Premium

Non-HMO

HMO

All Contracts
0

0

0.20%
0.01%

0.20%
0

All Contracts
Group, HMOs
Group managed care

--

0.10%

All Contracts
All Contracts
All Contracts
All Managed Care
Contracts
All Contracts
All Contracts
All Contracts
All Managed Care
Contracts
All Contracts
Plans with
participating eye
care professionals
All Contracts
Groups >20
All other
All Contracts
All Contracts
All Contracts
All Contracts
All Contracts
All Contracts

0.07%

0.07%

0.30%
0.07%

0.30%
0

-0.80%
0
0.19%

0.16%
0.80%
0
0.19%

0
0

0
0

0

0.04%

0.05%
0.03%
0.08%
0

0.05%
0.03%
0.08%
0

0
0.1%
0.1%
0
0
6.85%
3.75%
3.74%

0
0.1%
0.1%
0
0
7.32%
5.52%
4.12%

